The price of a healthcare service in the United States is not a price in any ordinary sense of the word. It is not a number that reflects cost plus margin, set by a seller and visible to a buyer before a transaction occurs. It is not the product of a competitive market in which buyers can compare options and choose based on value. It is the output of a layered system of list prices, confidential negotiated rates, government-set payment schedules, and after-the-fact billing that operates largely in the dark — and that produces outcomes for patients that range from confusing to financially catastrophic, in ways that are not accidental but structural.
Understanding how healthcare pricing actually works is necessary for evaluating any serious proposal to address healthcare costs. Reform proposals aimed at price transparency, drug pricing regulation, insurer market power, hospital consolidation, or administrative simplification are all, at bottom, proposals to change specific features of the pricing system. They cannot be evaluated without understanding what that system actually does, why it produces the outcomes it produces, and who benefits from its current operation.
This article describes the pricing system’s mechanics — chargemaster prices, negotiated rates, government payment schedules, pharmaceutical pricing, and the opacity that runs through all of them — and explains why that structure works against patients specifically rather than simply being complex. The administrative machinery that pricing complexity requires is examined in detail in The Administrative Burden and What It Costs. The role of consolidation in amplifying provider pricing power is examined in How Consolidation Drives Healthcare Costs.
Chargemaster Prices: The Fiction at the Top
Every hospital maintains a document called the chargemaster — a comprehensive list of prices for every service, procedure, supply, and accommodation the hospital provides. A chargemaster might contain tens of thousands of line items, each with an assigned price. These prices are the starting point for all hospital billing.
They are also largely fictional as transaction prices. Almost no one pays chargemaster prices. Medicare pays its own administratively set rates, which are substantially lower. Medicaid pays even lower state-set rates. Private insurers pay negotiated rates that are somewhere between Medicaid rates and chargemaster prices, depending on the insurer’s market power and the specific contract. The only people who are billed at or near chargemaster prices are the uninsured — people with no coverage and no negotiated rate on their behalf — and patients who receive care from out-of-network providers, where the insurer’s negotiated rates do not apply.
The gap between chargemaster prices and what most payers actually pay is enormous. A procedure with a chargemaster price of $10,000 might generate a Medicare payment of $3,500, a large-insurer negotiated payment of $5,000, a small-insurer payment of $7,500, and a bill to an uninsured patient of $10,000 — with the hospital’s actual cost of providing the service possibly $2,800. These are not hypothetical ratios. Studies of hospital pricing have documented chargemaster prices ranging from two to ten times Medicare reimbursement rates, with the highest markups concentrated in certain high-profit service lines and in markets where hospital systems face limited competition.
The chargemaster system serves several functions that benefit hospitals even though it does not represent actual transaction prices. It creates an anchor for negotiation — starting the negotiation at an inflated figure ensures that the negotiated rate, even if significantly discounted, remains favorable. It creates the appearance of discounting — an insurer that negotiates a 40 percent discount from chargemaster can represent this to employers as aggressive cost management, even if the post-discount rate is still substantially above cost. And it maximizes revenue from the uninsured and out-of-network patients who lack the negotiating position to achieve discounts — the population least able to absorb high costs.
Hospital financial assistance programs — charity care policies that reduce or eliminate bills for low-income uninsured patients — partially address the harm of chargemaster billing to the most economically vulnerable patients. But these programs vary enormously in generosity, are inconsistently advertised, require patients to navigate application processes, and apply only to qualifying patients. The uninsured patient who does not know about financial assistance, does not apply, or does not meet the income threshold faces the full chargemaster bill — a figure that may bear no relationship to what any insurer would pay for the same service.
Negotiated Rates: The Hidden Architecture of Insurance Pricing
For the insured majority, the relevant price is not the chargemaster rate but the negotiated rate — the price that the patient’s insurer has contracted to pay for each service at each provider. These negotiated rates are the actual transaction prices of most American healthcare. They are also almost entirely invisible.
Negotiated rates are confidential by contract. The rates that a specific insurer pays a specific hospital or physician group are proprietary information, not publicly disclosed. This confidentiality serves the interests of both parties to the negotiation: hospitals prefer that competing hospitals not know their rates, and insurers prefer that competing insurers not know how effectively they negotiate. The result is that employers who purchase health coverage cannot determine what their insurer is actually paying for care, patients cannot compare what different providers would cost their insurer before seeking care, and the market mechanisms that would theoretically discipline pricing through comparison and competition cannot function.
Price transparency regulations have attempted to pierce this opacity. The Hospital Price Transparency Rule, which took effect in 2021, requires hospitals to publish their negotiated rates with private insurers in machine-readable files. The Transparency in Coverage Rule, which extended similar requirements to insurers, took effect in 2022. These requirements represent a genuine policy shift — for the first time, some of the negotiated rate information that was previously entirely confidential is technically available.
In practice, compliance has been inconsistent and the published data has been difficult to use. The machine-readable files that hospitals publish are enormous, technically complex, and not designed for patient use. They require sophisticated data infrastructure to process. Research on compliance found that many hospitals were publishing incomplete, inaccurate, or technically inaccessible files in the period following the rule’s implementation. The gap between the regulatory intent — a patient should be able to determine in advance what a procedure will cost — and the practical reality has been large.
Even where the data is accessible, the price transparency framework does not address a deeper problem: negotiated rates vary not just by insurer but by specific plan, specific network tier, and specific market. A patient with employer-sponsored insurance through a large national insurer may be in a plan that uses a narrow network with favorable rates at certain providers, or a broad network with less favorable rates, or a tiered network that requires higher cost-sharing for certain hospitals — and the interaction between the negotiated rate and the patient’s specific cost-sharing structure determines what the patient actually pays. The price transparency requirements publish a negotiated rate; they do not tell the patient what they will owe after applying their specific plan’s deductible, coinsurance, and out-of-pocket maximum.
Government Payment Rates: Setting the Floor
For approximately 40 percent of Americans covered by Medicare and Medicaid, prices are not negotiated but administratively set by government. Understanding how these rates are set, and how they relate to private rates, is essential for understanding the overall pricing structure.
Medicare payment rates for physician services are calculated through a formula involving relative value units — a measure of physician work, practice costs, and malpractice risk associated with each service — multiplied by a conversion factor that translates relative value into dollars. The conversion factor is set annually by Congress, and its management has been a persistent source of conflict between physicians and policymakers: the Sustainable Growth Rate formula that governed physician payments for years produced annual payment cuts that Congress repeatedly overrode with temporary patches, a cycle that was finally ended by the Medicare Access and CHIP Reauthorization Act of 2015, which replaced it with a value-based payment framework that has its own complexity and controversy.
Medicare hospital payment operates through the Prospective Payment System introduced in 1983, which pays a fixed amount per hospitalization based on the patient’s diagnosis — the Diagnosis Related Group — rather than reimbursing actual costs incurred. This system was designed to create efficiency incentives: a hospital that treats a patient for less than the DRG payment keeps the difference; a hospital that spends more absorbs the loss. In practice, the incentive has contributed to shorter hospital stays and more aggressive discharge practices, with downstream effects on readmission rates and post-acute care demand.
Medicaid rates are set by states within federal guidelines and are consistently lower than Medicare rates — often substantially lower. The gap between Medicaid rates and commercial rates creates a two-tier access problem: providers who cannot cover their costs seeing Medicaid patients at Medicaid rates limit their Medicaid caseloads, producing access problems for low-income populations that show up as longer wait times, fewer available providers, and reliance on safety-net institutions that serve disproportionate Medicaid populations. A physician practice that is financially viable seeing a mix of commercial and Medicare patients may be financially marginal if it sees a high proportion of Medicaid patients — not because the physicians are unwilling but because the payment rates do not cover operating costs at scale.
The relationship between government payment rates and private rates is not independent. Because Medicare and Medicaid together cover a large share of patients, the rates they pay affect the overall revenue structure of healthcare providers. Providers typically argue that low government payment rates must be cross-subsidized by higher commercial rates — that what they lose on government-paid patients must be recovered from commercially insured patients. The empirical evidence on cost-shifting is debated: some research supports the cross-subsidy story, other research finds that providers with market power use that power to raise commercial rates regardless of government payment levels. The interaction between government rate-setting and commercial negotiation is one of the most consequential and contested dynamics in healthcare economics.
Pharmaceutical Pricing: A System Built on Opacity and Intermediaries
Prescription drug pricing in the United States is among the most complex and least transparent segments of an already opaque pricing system. The price a patient pays for a drug is the output of a chain of transactions involving manufacturers, wholesalers, pharmacy benefit managers, insurers, and pharmacies — each of which extracts a margin and each of which operates with limited transparency to the other parties in the chain or to the patient at the end of it.
Drug manufacturers set launch prices for new drugs based on what the market will bear — a calculation that in the United States, unlike in other wealthy countries, occurs in the absence of centralized price negotiation. A pharmaceutical company introducing a new drug in Germany or Canada negotiates with a government body that represents the entire national market and that has the authority to refuse coverage at unacceptable prices. In the United States, until the limited authority created by the Inflation Reduction Act of 2022, no such negotiation occurred for Medicare: manufacturers set prices and Medicare paid them, with the prohibition on negotiation explicitly written into the statute that created Medicare Part D in 2003.
Pharmacy Benefit Managers — PBMs — are intermediaries that manage prescription drug benefits for insurers and employers. They negotiate rebates with manufacturers: a manufacturer whose drug is placed on favorable formulary tiers — covered at lower cost-sharing — pays rebates to the PBM. These rebates reduce the net price paid by the PBM’s clients but may not reduce the price paid by patients, whose cost-sharing is often calculated based on the drug’s list price rather than the post-rebate net price. The list price and the net price of many drugs differ substantially — and the opacity between them means that the patient’s out-of-pocket cost may be calculated on a figure that does not reflect what the insurer actually pays.
The consequences of this pricing structure are visible in the gap between what Americans pay for drugs and what people in other wealthy countries pay for the same drugs. The same insulin, manufactured by the same company, costs several times more in the United States than in Canada. The same cancer medication costs multiples more than in France or Germany. This is not primarily explained by higher American incomes or different regulatory requirements — it is explained by the pricing power manufacturers exercise in a market without centralized negotiation, and by the opacity of the intermediary chain that distributes rather than reduces that pricing power.
The Inflation Reduction Act’s drug price negotiation provisions represent the first significant constraint on this structure for Medicare — covering a limited number of high-cost drugs with large Medicare expenditures. The effects on the drugs covered are real and significant. The scope of the authority — limited to Medicare, covering only a small number of drugs in the first years of implementation — leaves the broader pricing structure largely intact.
Surprise Billing: When Pricing Opacity Becomes Acute Harm
Before the No Surprises Act took effect in 2022, one of the most acutely harmful features of healthcare pricing was surprise billing: the practice of billing patients at out-of-network rates for care received at in-network facilities. The mechanism was straightforward and the harm was severe.
A patient who went to an in-network hospital for a procedure might have confirmed that the hospital, the surgeon, and the anesthesiologist were all in-network — but not have known that the facility also used out-of-network specialists for interpretation of lab results, assistance in surgery, or other services that the patient had no ability to select or decline. When those providers billed at their out-of-network rates, the insurer paid little or nothing, and the patient was responsible for the balance. Surprise bills of tens of thousands of dollars for patients who had done everything right — who had gone to in-network facilities and followed their insurer’s requirements — were not unusual.
The No Surprises Act addressed this in emergency settings and for certain scheduled care: out-of-network providers at in-network facilities are now prohibited from billing patients more than in-network cost-sharing amounts for most services. The disputes between out-of-network providers and insurers about the appropriate payment rate are resolved through an arbitration process rather than being transferred to the patient. This is a genuine protection — the acute harm of surprise billing has been substantially reduced for the services the law covers.
What the No Surprises Act did not address is the broader structure of pricing opacity that made surprise billing possible and that continues to produce financial harm in less acute forms. Patients who receive care from out-of-network providers in scheduled settings not covered by the law, patients who are balance-billed in states without additional protections, and patients who receive services that fall outside the law’s coverage — all continue to face pricing dynamics they could not have anticipated or managed.
Who Benefits From Opacity
The opacity that runs through the American healthcare pricing system is not incidental. It is structurally maintained because it serves the interests of powerful actors in the system — interests that are not aligned with patients’ interests in knowing what care will cost before they receive it.
Hospitals benefit from chargemaster opacity because it maximizes their negotiating starting position and their revenue from uninsured and out-of-network patients. Insurers benefit from negotiated rate confidentiality because it prevents employers and patients from evaluating the quality of their negotiation or comparing what other insurers pay. Pharmaceutical manufacturers benefit from list price opacity because the gap between list and net prices obscures the actual cost of drugs and complicates reform efforts. PBMs benefit from rebate opacity because it allows them to capture value from the drug pricing chain without transparent accountability for what they contribute.
The people who do not benefit from opacity are patients: the patient who cannot find out what a procedure will cost before deciding whether and where to have it done, the patient whose cost-sharing is calculated on a list price that no one actually pays, the patient whose surprise bill reflects pricing dynamics they had no way to anticipate, and the patient who delays or forgoes care because they cannot assess whether they can afford it.
Price transparency is a necessary but not sufficient condition for a functional pricing market in healthcare. Even with full transparency, the conditions for effective price competition — informed buyers, meaningful choice, standardized products — are often absent in healthcare: a patient having a heart attack cannot shop for an emergency room, a patient whose oncologist is at one hospital cannot readily transfer their care to compare prices, and the quality variation between providers is real and difficult for patients to assess. But opacity without transparency is worse — it produces the current situation in which the absence of price information compounds the other barriers to effective healthcare markets in ways that consistently work against patients.
The structural reforms that would change this — centralized price negotiation, global budget approaches, all-payer rate setting, administrative simplification — are examined in The Full Range of Reform Proposals. The administrative machinery that pricing complexity requires — the billing departments, the prior authorization apparatus, the claims adjudication infrastructure — is examined in The Administrative Burden and What It Costs. Together, they describe a pricing system whose complexity is not an unfortunate accident but the accumulated product of decisions that have consistently prioritized the interests of payers, providers, and intermediaries over those of the patients who ultimately bear its costs.
The people with the most granular knowledge of how this system operates — the hospital billing manager who navigates chargemaster negotiations, the physician practice administrator who manages prior authorizations and out-of-network disputes, the patient advocate who helps people fight surprise bills, the patient who has tried to find out in advance what a procedure would cost and discovered that no one could tell them — carry knowledge of how the system actually functions that belongs in any serious deliberation about changing it.
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.